Sign In
Buy CLPT
$14.94
+0.360 (+2.47%)
At Close: Jul 31, 2026
Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO , June 20, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc. a
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
12:56pm, Monday, 03'rd Jun 2024
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
09:00am, Saturday, 01'st Jun 2024
SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
10:56am, Wednesday, 29'th May 2024
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
11:01am, Monday, 13'th May 2024
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
ClearPoint Neuro, Inc. (CLPT) Q1 2024 Earnings Call Transcript
10:40pm, Tuesday, 07'th May 2024
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Joe Burnett – Chief Executive Officer Danilo D'Alessandro – Chief Financial Offic
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
09:00am, Thursday, 02'nd May 2024
NEW YORK , May 2, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders. The investigation see
7 Penny Stocks That Could Make You a Fortune (If You Dare)
04:30pm, Wednesday, 01'st May 2024
Penny stocks are on the riskier end of the public equity spectrum. They are characterized by their low volume, affordable pricing, and the rapid pace at which their values can surge or plummet compare
ClearPoint Neuro: Macro-Induced Multiple Compression
02:30am, Thursday, 25'th Apr 2024
ClearPoint Neuro: Macro-Induced Multiple Compression
ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)
09:15am, Monday, 08'th Apr 2024
NEW YORK , April 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders. The investigation
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
09:36am, Wednesday, 27'th Mar 2024
ClearPoint Neuro (CLPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SOLANA BEACH, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation
ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript
11:39pm, Tuesday, 12'th Mar 2024
ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
06:41pm, Tuesday, 12'th Mar 2024
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.18 per share a year ago.
